source
- Astellas secures exclusive option on Audax Biosciences preclinical IL-12 cancer drugAstellas has taken an exclusive option to license a preclinical immuno-oncology asset from Audax Biosciences, an Australian biotech company. The asset is an IL-12 based cancer therapeutic that is…
- GSK vaccine sales miss expectations amid falling demand from adultsWith pressure on GSK’s vaccine business, analysts predict the U.K. pharma will face challenges as it prepares for the loss of exclusivity on a key product.